Skip to main content
OpenTrials
Completed

NCT Number: NCT00593918

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Infection with RSV is the most common cause of respiratory tract illnesses (LRIs) in the first 3 years of life. There are significant social and health care costs associated with RSV-LRIs. More than 3% of US children are hospitalized each year due to RSV and 500 die annually. Several longitudinal studies have also suggested that children who have RSV-LRIs are at substantially increased risk of developing asthma in the first 3 years after infection and bronchial hyperresponsiveness (BHR) many years after the primary infection. Mechanisms involved in RSV disease are not well understood. Recent reports suggest that RSV may initiate the innate immune response through the pattern recognition receptor, Toll like receptor-4 (TLR4). In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production. It has been suggested that such a mechanism may result in altered immune responses to RSV infection and different clinical outcomes. This research has direct application to improving our understanding of bronchiolitis in early childhood, particularly those factors that influence severity of the disease, and may have implications for possible therapy of patients with bronchiolitis in the future.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Parental or sibling history of asthma.
  • Child must be less than 24 months of age.
  • Presence of viral upper or lower respiratory tract symptoms.

Exclusion criteria

  • History of recurrent wheezing requiring systemic corticosteroids.
  • Prior history of lung disease.
  • Birth < 36 weeks gestation.
  • Immunodeficiency
  • Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV infection.
  • Congenital heart disease.
  • No history of parental or sibling asthma.
  • Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak symptoms from RSV would be expected to occur from 2-5 days into course of infection.

Treatment and study plan

Primary outcomes

  1. Nasal Interferon (IFN)-a2

    Time frame: 1-5 days during acute illness (not after day 5 of illness)

    Interferon a2 was measured from nasal lavage samples by Luminex multiplex assay.

  2. Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression

    Time frame: 1-5 days during acute illness (not after day 5 of illness)

    IL-2 measured from nasal lavage samples by Luminex multiplex assay

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Official study title

Innate Immunity and RSV Infection in Children

Acronym: IIRI

Important dates

Study start
2003
Primary completion
2008
Study completion
2008
First posted
Jan 15, 2008
Registry last updated
Oct 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.